133 Outcomes of Treatment for LOH Syndrome Assessed by Free Testosterone. (1st May 2022)

• Record Type: Journal Article
• Authors: Kaku, Y; Sato, K; Ooishi, A; Ishida, T; Okada, K; Chiba, K; Fujisawa, M
• Is Part Of: Journal of sexual medicine. Volume 19(2022)Supplement 2
• Page Start: S178
• Page End: S178
• Publication Date: 2022-05-01
• Subjects: Sexual disorders -- Periodicals; Sex -- Periodicals; Sexual health -- Periodicals; 616.69005
• DOI: 10.1016/j.jsxm.2022.03.406
• Languages: English
• ISSNs: 1743-6095

Abstract

ABSTRACT: Objective: Late-onset hypogonadism (LOH) is defined by reduced serum testosterone levels, and androgen replacement therapy (ART) is widely used. While serum total testosterone (TT) is used as an indicator for diagnosis and treatment for LOH in the United States and Europe, serum free testosterone (FT) is used in Japan. Patients with low FT levels (less than 8.5 pg/mL) are to be indicated for ART as LOH, and patients with moderate FT levels (between 8.5 pg/mL and 11.8 pg/mL) are also to be considered for ART as LOH borderline. In this study, we examined the outcomes of LOH and LOH borderline patients who were treated by ART. Methods: We examined Aging Male Symptom (AMS) scale scores of LOH (n=76) and LOH borderline patients (n=16) who were treated with ART for at least 6 months at our hospital. Results: In LOH patients, AMS score decreased from 52.1±12.3 to 41.5±12.2 (p<0.05). On the other hand, in borderline cases AMS score also decreased from 55.8±10.2 to 36.5±8.45 (p<0.05). There was no significant difference between two groups. Conclusion: ART improves AMS score both in LOH and LOH borderline patients, but there were no significant differences between two groups in this study. Disclosure: Work supported by industry: no.